|
| 36251491 | BLOODPAC: Collaborating to chart a path towards blood-based screening for early cancer detection. | Clin Transl Sci | 2023 |
| 36974724 | Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients. | J Urol | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36862389 | Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer-Calling Out the "Double Standard". | JAMA Oncol | 2023 |
| 36123219 | Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer. | Eur Urol | 2023 |
| 36115772 | Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer. | Eur Urol | 2023 |
| 34371138 | Evaluating Treatment Tolerability Using the Toxicity Index With Patient-Reported Outcomes Data. | J Pain Symptom Manage | 2022 |
| 35617398 | Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. | Science | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35643841 | Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. | Eur J Cancer | 2022 |
| 35538298 | Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. | Prostate | 2022 |
| 35670774 | The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer. | Clin Cancer Res | 2022 |
| 35568679 | Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. | Eur J Cancer | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35940363 | Evaluation of an Integrated Spectroscopy and Classification Platform for Point-of-Care Core Needle Biopsy Assessment: Performance Characteristics from Ex Vivo Renal Mass Biopsies. | J Vasc Interv Radiol | 2022 |
| 36357680 | Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. | Nat Med | 2022 |
| 35985981 | Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. | Eur Urol Oncol | 2022 |
| 36317634 | A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. | J Clin Invest | 2022 |
| 35131040 | Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. | Lancet Oncol | 2022 |
| 35247928 | Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation. | Mol Cancer Ther | 2022 |
| 35279418 | Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer. | Clin Genitourin Cancer | 2022 |
| 35277375 | Optimizing the future: how mathematical models inform treatment schedules for cancer. | Trends Cancer | 2022 |
| 35175783 | Spine Pain and Metastatic Prostate Cancer: Defining the Contribution of Nonmalignant Etiologies. | JCO Oncol Pract | 2022 |
| 34903480 | Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. | Clin Genitourin Cancer | 2022 |
| 34965947 | The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. | Clin Cancer Res | 2022 |
| 35020444 | Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide. | J Urol | 2022 |
| 34667026 | Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. | Clin Cancer Res | 2022 |
| 32726432 | Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. | J Natl Cancer Inst | 2021 |
| 33820782 | Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. | Clin Cancer Res | 2021 |
| 33894633 | Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. | Eur J Cancer | 2021 |
| 33497248 | Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. | J Clin Oncol | 2021 |
| 34020931 | Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). | Eur Urol Oncol | 2021 |
| 34059130 | Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. | Genome Med | 2021 |
| 34197212 | Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. | J Clin Oncol | 2021 |
| 33373705 | Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. | Urology | 2021 |
| 33419944 | Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with <sup>18</sup>F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study. | J Nucl Med | 2021 |
| 33441295 | PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. | Clin Cancer Res | 2021 |
| 32924093 | Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer. | Invest New Drugs | 2021 |
| 31412002 | Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. | Eur Urol Oncol | 2020 |
| 33717359 | Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancer. | J Circ Biomark | 2020 |
| 32001144 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. | Eur Urol | 2020 |
| 31672861 | Toward Standardization of Preanalytical Procedures for Cell-Free DNA Profiling. | Clin Chem | 2020 |
| 32057715 | A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. | Clin Genitourin Cancer | 2020 |
| 32017048 | Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases. | Clin Pharmacol Ther | 2020 |
| 31830211 | Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. | JAMA Oncol | 2020 |
| 32094488 | Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2020 |
| 31648903 | Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer. | Eur Urol | 2020 |
| 33106634 | Cancer therapy shapes the fitness landscape of clonal hematopoiesis. | Nat Genet | 2020 |
| 33184097 | Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer. | ESMO Open | 2020 |